Update on the pharmacokinetics and pharmacodynamic properties, drug interactions and therapeutic usage of benzodiazepines;Mise à jour sur les considérations pharmacocinétiques, pharmacodynamiques et les interactions médicamenteuses dans le choix d'une benzodiazépine

Annales Medico-Psychologiques

Volumn 166, Issue 7, 2008, Pages 585-594

  Landry, P ^a   Gervais, M ^a   O'Connor, K P ^a  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

Author keywords

Benzodiazepine; Drug Interaction; Pharmacodynamic; Pharmacokinetic

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ALPRAZOLAM; BENZODIAZEPINE; BROMAZEPAM; CALCIUM CHANNEL BLOCKING AGENT; CHLORDIAZEPOXIDE; CHLORIDE ION; CLONAZEPAM; CLORAZEPATE; CORTICOSTEROID; CYTOCHROME P450; DIAZEPAM; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; GAMMA BUTYROBETAINE; KETOCONAZOLE; LORAZEPAM; MIDAZOLAM; NITRAZEPAM; OXAZEPAM; PROTEIN; SERTRALINE; TEMAZEPAM; TRIAZOLAM;

ARTICLE; AUTOREGULATION; BRAIN STEM; CENTRAL NERVOUS SYSTEM; CHANNEL GATING; CHLORIDE TRANSPORT; CIGARETTE SMOKING; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BINDING; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INHIBITION; DRUG INTERACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERANCE; DRUG USE; ELDERLY CARE; ENZYME ACTIVITY; GRAPE JUICE; HUMAN; INSOMNIA; LIMBIC SYSTEM; LIVER DISEASE; LIVER METABOLISM; MAJOR DEPRESSION; MOOD; NERVE CELL; PHARMACODYNAMICS; PHARMACOKINETICS; ROSETTE FORMATION; SEDATION; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT;

EID: 49249120752     PISSN: 00034487     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amp.2008.06.008     Document Type: Article

References (49)

1. Anseau M., von Frenckell R., and Jacqmin P. Comparison of sublingual and oral prazepam in normal subjects. 1: Clinical data. Neuropsychobiology 18 (1987) 77-82
2. Ballenger J.C. Benzodiazepines. In: Schatzberg A.F., and Nemeroff C.B. (Eds). The american psychiatric press textbook of psychopharmacology (1995), American Psychiatric Press, Washington
3. Benet L.Z., Kroetz D.L., and Sheiner L.B. Pharmacokinetics. The dynamics of drug absorption, Distribution, and Elimination. In: Goodman, and Gilman (Eds). The pharmacological basis of therapeutics (1996), McGraw Hill, New York
4. A receptor modulator. Eur Neuropsychopharmacol 13 (2003) 411-423
5. Cameroun O.G., Huang G.C., Nichols T., et al. Reduced γ-aminobutyric acid-benzodiazepine binding sites in insular cortex of individuals with panic disorder. Arch Gen Psychiatry 64 (2007) 793-800
6. Cates M.E., Bishop M.H., Davis L.L., Lowe J.S., and Woolley T.W. Clonazepam for the treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. Ann Pharmacother 38 (2004) 1395-1399
7. Chouinard G., and Nelson J. Benzodiazepines: An update on their mechanisms of action. Can J Clin Pharmacol 3 (1996) 75-82
8. Chouinard G., and Nelson J. Benzodiazépines: mechanisms of action and clinical indications. In: Baskys A., and Remington G. (Eds). Brain mechanisms and psychotropic drugs (1996), CRC Press, New York
9. Chouinard G., Lefko-Singh K., and Teboul E. Metabolism of anxiolytics and hypnotics: Benzodiazepines, buspirone, zoplicone, and zolpidem. Cell Mol Neurobiol 19 (1999) 533-552
10. Cowley D.S., Roy-Byrne P.P., and Greenblatt D.J. Benzodiazepines: pharmacokinetics and pharmacodynamics. In: Roy-Byrne P.P., and Cowley D.S. (Eds). Benzodiazepines in clinical practice: risks and benefits (1991), American Psychiatric Press, Washington
11. Crone C.C., and Gabriel G.M. Treatment of anxiety and depression in transplant patients. Clinical Pharmacokinetic 43 (2004) 361-394
12. Curran H.V. In: Tulving E., and Craik F.I.M. (Eds). The Oxford Handbook of Memory (2000) [p. 539-54]
13. Desai H.D., Seabolt J., and Jann M.W. Smoking in patients receiving psychotropic medications. A pharmacokinetic perspective. CNS Drugs 15 (2001) 469-494
14. Eros E. A population-based case-control teratologic study of nitrazepam, medazepam, tofisoam, alprazolam and clonazepam treatment during pregancy. Eur J Obstet Gynecol Reprod Biol 101 (2002) 147-154
15. Greenblatt D.J., Allen M.D., McLaughlin D.R., Harmatz J.S., and Sahder R.I. Diazepam absorption: Effects of antacids and food. Clin Pharmacol Ther 24 (1978) 600-609
16. Greenblatt D.J., Divoll M., Harmatz J.S., and Shader R.I. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular and oral lorazepam. J Pharm Sci 71 (1982) 248-252
17. Greenblatt D.J., Shader R.I., and Abernethy D.R. Current status of benzodiazepines, parties I. New Eng J Med 309 (1983) 354-358
18. Greenblatt D.J., Shader R.I., and Abernethy D.R. Current status of benzodiazepines, parties II. New England Journal of Medecine 309 (1983) 410-415
19. Greenblatt D.J., Harmatz J.S., von Moltke L.L., Wright C.E., and Shader R.I. Age and gender effects on the pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 76 (2004) 467-479
20. Guelpin E., Bonne O., Peri T., Brandes D., and Shalev A.Y. Treatment of recent trauma survivors with benzodiazepines: A prospective study. J Clin Psychiatry 57 (1996) 390-394
21. Guengerich F.P. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 43 (1997) 7-35
22. Hallam K.T., Olver J.S., McGrath C., and Norman T.R. Comparative cognitive and psychomotor effects of single doses of Valariana officianalis and triazolam in healthy volunteers. Hum Psychopharmacol 18 (2003) 619-625
23. Hobbs W.R., Rall T.W., and Verdoorn T.A. Hypnotics and sedatives; Ethanol in goodman and gilman, the pharmacological basis of therapeutics (1996), McGraw Hill, New York
24. Hwang G., Kim H.R., Park S.H., Kim S.H., Park S.R., and Kim G.H. Do benzodiazepines extend the duration of follow-up treatment in patients with bipolar disorder?. Hum Psychopharmacol Clin Exp 21 (2006) 319-325
25. e ed. (2003), Williams & Wilkins, Baltimore
26. Kassam A., and Patten S.B. Canadian Trends in benzodiazepine and zopiclone. Can J Clin Pharmacol 13 (2006) 121-127
27. Klimke A., and Klieser E. Sudden death after intravenous application of lorazepam in a patient treated with Clozapine. Am J Psychiatry 15 (1994) 780
28. Landry P., and Mainguy N. Conseils cliniques pour faciliter le sevrage des benzodiazépines. Sante Ment Que 28 (2003) 43-58
29. Le Mellédo J.M., Legrand J.M., Bradwejn J., and Dufour N. Anxiolytiques et hypnotiques. In: Lalonde P., Aubut R., and Grunberg F. (Eds). Psychiatrie clinique: une approche bio-psycho-sociale vol. 2 (2001), Gaëtan Morin, Boucherville p. 1138-59.
30. Low K., Crestani F., Keist R., et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290 (2000) 131-134
31. Malizia A.L. What do brain imaging studies tell us about anxiety disorders?. J Psychopharmacol 13 (1999) 372-378
32. A receptor α1 subtype. Nat Neurosc 3 (2000) 587-592
33. A receptor modulators upon discontinuation of chronic benzodiazepine treatment in rhesus monkeys. Psychopharmacology 192 (2007) 135-145
34. Möller H.J. Effectiveness and safety of benzodiazepines. J Clinl Psychopharmacology 19 (1999) 2S-11S
35. Morishita S., and Aoki S. Clonazepam in the treatment of prolonged depression. J Affective Dis 53 (1999) 275-278
36. Morishita S., and Aoki S. Clonazepam augmentation of antidepressants: Does it distinguish unipolar from bipolar depression?. J Affective Dis 71 (2002) 217-220
37. Moroz G. High-potency benzodiazepines: Recent clinical results. J Clin Psychiatry 65 (2004) 13S-18S
38. A-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179 (2001) 390-396
39. Ochs H.S., et al. Bromazepam pharmacokinetics: Influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther 41 (1987) 562-570
40. O'Connor K., Marchand A., Bélanger L., Mainguy N., Landry P., Savard P., et al. Psychological distress and adaptational problems associated with benzodiazepine withdrawal and outcome: A replication. Addict Behav 29 (2004) 583-593
41. Otto M.W., Bruce S.E., and Deckersbach T. Benzodiazepine use, cognitive impairment, and cognitive-behavioral therapy for anxiety disorders: Issues in the treatment of patientes in need. J Clin Psychiatry 66 (2005) 34S-38S
42. Rickels K., Schweizer E., Case W.G., and Greenblatt D.J. Long-term therapeutic use of benzodiazepines. Effects of abrupt discontinuation. Arch Gen Psychiatry 47 (1990) 889-907
43. Scott E.L., Pollack M.H., and Otto M.W. Clinician response to treatment refractory panic disorder: A survey of psychiatrists. J Nerv Mental Dis 187 (1999) 755-757
44. Sibille E., Pavlides C., Benke D., and Toth M. Genetic inactivation of serotonin (1A) receptor in mice results in downregulation of major GABA(A) receptor α subunits, reduction of GABA(A) receptor binding, and benzodiazepine-resistant anxiety. J Neurosci 20 (2000) 2758-2765
45. Smith W.T., Londborg P.D., Glaudin V., and Painter J.R. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression?. J Affective Dis 70 (2002) 251-259
46. Sugimoto K., Araki N., Ohmori M., Harada K., Cui Y., Tsuruoka S., et al. Interaction between grapefruit juice and hypnotic drugs: Comparison of triazolam and quazepam. Eur J Clin Pharmacol 62 (2006) 209-215
47. Tiihonen J., Kuikka J., Rasanen P., et al. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: A fractal analysis. Mol Psychiatry 6 (1997) 460-471
48. Winkler D., Willeit M., Wolf R., Stamenkovic M., Tauscher J., Pjrek E., et al. Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder. Eur Neuropsychopharmacol 13 (2003) 129-134
49. Zacher J.L., and Roche-Desilets J. Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam. J Clin Psychiatry 66 (2005) 1614-1615